Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vivoryon Therapeutics has reported promising results from its Phase 2 studies on varoglutamstat, showcasing significant improvements in kidney function for patients. The company highlights the potential of varoglutamstat as a treatment for diabetic kidney disease, with plans to advance its clinical development. Financially, Vivoryon anticipates sufficient funds to support operations until Q3 2025, reflecting a strong position for further growth.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.